Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

13.13
+0.78006.32%
Post-market: 13.10-0.0300-0.23%19:53 EDT
Volume:1.34M
Turnover:17.31M
Market Cap:1.00B
PE:-9.12
High:13.26
Open:12.52
Low:12.38
Close:12.35
52wk High:13.82
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.75
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:7.97
PE(LYR):-18.21

Loading ...

Candel Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk

TIPRANKS
·
Mar 13

Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate

Benzinga Earnings
·
Mar 12

Candel Therapeutics Q4 operating loss misses analyst expectations

Reuters
·
Mar 12

BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million

Reuters
·
Mar 12

Candel Therapeutics Q4 Income From Operations USD -15.752 Million VS. Ibes Estimate USD -13.9 Million

THOMSON REUTERS
·
Mar 12

Candel Therapeutics Q4 Basic EPS USD -0.54

THOMSON REUTERS
·
Mar 12

Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Dow Jones
·
Mar 12

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

GlobeNewswire
·
Mar 09

Candel Therapeutics Grants New Hire Options for 20,000 Shares Under 2025 Inducement Plan

Reuters
·
Mar 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 03

Candel Therapeutics Director Paul B. Manning Acquires Common Shares

Reuters
·
Feb 27

Candel Therapeutics CEO Paul Peter Tak to Present at TD Cowen’s 46th Annual Health Care Conference

Reuters
·
Feb 24

Candel Therapeutics Announces Equity Offering to Fund CAN-2409

TIPRANKS
·
Feb 23